MARÍA DOLORES
CABALLERO BARRIGÓN
Investigadora en el periodo 1998-2022
Hospital Universitario Puerta de Hierro
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (25)
2021
-
Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study
British Journal of Haematology, Vol. 192, Núm. 1, pp. 82-99
-
Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers
Blood Advances, Vol. 5, Núm. 24, pp. 5588-5598
2020
-
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group
Annals of Hematology, Vol. 99, Núm. 4, pp. 799-808
2018
-
A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group
American Journal of Hematology, Vol. 93, Núm. 7, pp. 867-873
2017
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
2016
-
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial
Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899
-
The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: A pilot trial from the GETH and GELLC (CLL4 trial)
Bone Marrow Transplantation
2014
-
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase II clinical trial
Haematologica
-
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase II clinical trial
Haematologica, Vol. 99, Núm. 3, pp. 505-510
-
Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis
Haematologica
-
Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585
2013
-
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group
Haematologica, Vol. 98, Núm. 10, pp. 1563-1570
-
Incidence Of Chemotherapy-Induced Neutropenia And Current Practice Of Prophylaxis With Granulocyte Colony-Stimulating Factors In Cancer Patients In Spain: A prospective, observational study
European Journal of Cancer Care, Vol. 22, Núm. 4, pp. 513-521
2011
-
Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma
Leukemia and Lymphoma, Vol. 52, Núm. SUPPL. 3, pp. 1-14
2010
-
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era
European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328
-
Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia
Annals of Hematology, Vol. 89, Núm. 11, pp. 1073-1080
2006
-
Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigen-identical sibling donors: Influence of stem cell source [13]
Leukemia
-
Erratum: Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients (Annals Hematology (2006) 10.1007/s00277-005-0073-1)
Annals of Hematology
-
Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients [14]
Leukemia
-
Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients
Annals of Hematology, Vol. 85, Núm. 6, pp. 400-406